Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This study compares the immunogenity and safety of quadrivalent inactivated influenza
vaccines. The experimental group receives the quadrivalent influenza vaccine developed by
Sinovac Biotech Co., Ltd and the control group immunized with Vaxigrip Tetra™. The group has
1600 persons from general population 3 years and older. The design is double-blind and
randomized. The primary outcome is the immunogenicity against the 4 strains of influenza
included in both vaccines.